NuPathe Gets $114M Takeover Bid After Inking Deal With Endo

Law360, New York (January 8, 2014, 5:02 PM EST) -- Specialty pharmaceuticals company NuPathe Inc. received a $114.3 million takeover bid from Israel-based Teva Pharmaceutical Industries Ltd., less than a month after NuPathe agreed to sell itself to Endo Health Solutions Inc. for $105 million, according to an SEC filing Tuesday.

Teva’s offer is largely similar to Endo’s, but offers investors $3.65 per share versus Endo’s offer of $2.85 per share, the SEC filing said. Teva also said it would cover any breakup fee levied on NuPathe for nixing its deal with Endo, which was set...
To view the full article, register now.